Enterogermina Forte 10 vials x 5 ml oral suspension, Sanofi

4 billion in the bottle, 4 trillion in the gut ¹

Restores and protects the flora
intestinal4 from the first day ²

Enterogermin restores and protects the intestinal flora4, both in adults and in children, when it is affected by:

• Diarrhea
• Irregular transit
• Disordered eating
• Prolonged stress
• Side effects of antibiotics* ³

Unbalanced diet

Viral/bacterial infections in children

Traveled

Restores and protects the intestinal flora ⁴

100% of Intelli-Spores reach the gut ¹ alive

It helps to improve the side effects of antibiotics ^*3

Easy to administer

Clean formula - no sugar, no gluten

No taste, no smell

How Intelli-Spores works

- 100% of Intelli-Spores arrive alive in the intestine1, surviving the action of gastric acid.

- Enterogermina acts starting from the first day ²

^- Intelli-Spores multiply 1000 times to restore and protect the intestinal flora. ⁴ 4.

Enterogermina FORTE is a probiotic that contains spores of a multiresistant strain of Bacillus clausii, an antidiarrheal preparation for restoring the intestinal microflora.

Action

Bacillus clausii spores, which are present in the preparation, are usually present in the intestine and do not show pathogenic activity. Thanks to the action of Bacillus clausii, the preparation restores the suppressed intestinal microflora as a result of treatment with preparations that lead to dysbiosis. In addition, due to the ability of Bacillus clausii to synthesize various vitamins, especially from the B group, the preparation helps to correct disvitaminosis caused by the use of antibiotics or chemotherapeutic preparations. Can be used during pregnancy and breastfeeding.

BENEFITS

Probiotics have several functions in the human body:

Suppression of pathogenic microflora;

Restoration of normal microflora;

Synthesis of vitamins, mainly of the B group.

The antimicrobial effect of probiotics containing Bacillus clausii begins within 2 hours.
The use of a probiotic reduces the following side effects from the first day of administration of the antibiotic: abdominal pain;

The probiotic has immunomodulatory activity.

Bacteria of the Bacillus clausii strain contained in probiotics are among the most studied probiotic microorganisms.

These are:

Resistant to gastric juice, bile acids, antibacterial preparations.

They have a studied mechanism of action and a proven high safety profile.

Microorganisms of the Bacillus clausii strain are recommended by the World Organization of Gastroenterology and are approved for use during pregnancy and lactation.

Indications for use
Treatment and prevention of intestinal dysbiosis and associated endogenous dysvitaminosis.

Adjunctive therapy aimed at restoring the normal intestinal microflora, which is disturbed during treatment with antibiotics or chemotherapeutic preparations.

Acute and chronic gastrointestinal diseases in infants associated with intoxication or intestinal dysbiosis and dysvitaminosis.

Contraindications
Hypersensitivity to the active substance or to any of the excipients.

Method of administration and dosage

Adults 5 ml (1 vial) per day.

Children: the preparation is used in infants and children in a dose of 5 ml (1 bottle) per day.

The contents of the vial are administered undiluted or diluted in water or other beverages (eg milk, tea or orange juice).

This medicine is for oral use only.

It is not administered parenterally or otherwise.

The duration of the treatment is determined by the doctor, depending on the patient's condition and the evolution of the disease.

Treatment and prevention of intestinal dysbiosis and associated endogenous dysvitaminosis - 5-7 days.

Auxiliary therapy is aimed at restoring the normal intestinal microflora, which is disturbed during treatment with antibiotics or chemotherapeutic preparations - during antibiotic therapy (on average 5-10 days).

Acute and chronic gastrointestinal diseases in infants associated with intoxication or intestinal dysbiosis and disvitaminosis: acute - 5-7 days, chronic - up to 30 days.

BOYS
The preparation can be used in children older than 28 days.

Use during pregnancy or breastfeeding

There are no contraindications for the use of the preparation during pregnancy and breastfeeding.

Structure
Active ingredient: spores of a multiresistant strain of Bacillus clausii; 1 bottle of 5 ml contains spores of the multiresistant strain of Bacillus clausii - 4x109.

Excipients : purified water.

Storage conditions
Keep out of reach of children at temperatures below 30°C.

To avoid contamination of the suspension, the bottle must not be opened beforehand.

are you traveling Take care of your intestinal flora

Traveling can upset your routine - including your digestion. New foods, different water or time zone changes can affect the balance of intestinal flora, leading to bloating, diarrhea or slow intestinal transit. To feel good throughout the vacation, wash your hands often and eat fresh and well-cooked food. A balanced diet, rich in fiber and nutrients, helps to maintain a healthy intestinal flora and a general state of well-being, no matter where you travel.

Mode of administration

Step 1 - Shake

Step 2 - Open

Step 3 - Drink

Details

*Penicillin G; Oxacillin; Cefuroxime; Cefotaxime; Ceftriaxone; Cefepime; Erythromycin; Azithromycin; Clarithromycin; Spiramycin; Clindamycin; Lincomycin; Metronidazole; Telithromycin.

Vecchione A. et al. Compositional Quality and Potential Gastrointestinal Behavior of Probiotic Products Commercialized in Italy. Front Med (Lausanne). 2018;5:59.

E. Ghelardi et al. Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore-based probiotic formulation. Appl Microbiol. 2015;119:552-9.

Abbrescia, A. et al. "Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation." Current Medicinal Chemistry, vol 1,2 (2014): 102–110. doi:10.2174/2212707002666150128195631.

Mazzantini, D., Calvigioni, M., Celandroni, F., Lupetti, A. and Ghelardi, E. (2022). In vitro assessment of probiotic attributes for strains contained in commercial formulations. Scientific Reports, 12(1), p.21640.

Calvigioni, M., Bertolini, A., Codini, S., Mazzantini, D., Panattoni, A., Massimino, M., Celandroni, F., Zucchi, R., Saba, A. and Ghelardi, E. (2023). HPLC-MS-MS quantification of short-chain fatty acids actively secreted by probiotic strains. Frontiers in Microbiology, 14, p.112414